drugset / Trial / NCT00403221

Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer

NCT00403221 ↗

Phase 1 Completed 19 enrolled Baylor College of Medicine
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to conduct a Phase I clinical trial involving in situ RTVP-1 gene therapy for prostate cancer. We will conduct necessary safety evaluations on a new adenovirus that contains the human genes for RTVP-1. This virus will then be evaluated for safety in men with prostate cancer prior to radical prostatectomy. Based on the preclinical data, we hope that this treatment will induce not only a local cytotoxic and antiangiogenic effect but also, a systemic antitumor immune response capable of eradicating micrometastatic disease (the reason for recurrence in many of these patients).

Timeline

Start
2006-08
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject RTVP-1 Gene Gene therapy (AAV / viral vector) 1e+10 unknown Other
Subject RTVP-1 Gene Gene therapy (AAV / viral vector) 5e+10 unknown Other
Subject RTVP-1 Gene Gene therapy (AAV / viral vector) 1e+11 unknown Other
Subject RTVP-1 Gene Gene therapy (AAV / viral vector) 5e+11 unknown Other
Subject RTVP-1 Gene Gene therapy (AAV / viral vector) 1e+12 unknown Other
Subject RTVP-1 Gene Gene therapy (AAV / viral vector) 5e+12 unknown Other

Indications